Page last updated: 2024-12-06

1,2,3,4-tetrahydroquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2,3,4-tetrahydroquinoline is a heterocyclic aromatic compound with a quinoline core structure. It is a colorless liquid with a characteristic odor. This compound is known for its versatile synthetic utility and has been studied for its potential biological activities, including anti-inflammatory and analgesic properties. It can be synthesized via various methods, including the reduction of quinoline, the reaction of aniline with cyclohexanone, and the cyclization of N-(2-aminoethyl)benzaldehyde. Research focuses on its potential as a precursor for pharmaceuticals and fine chemicals. Its unique structural features and potential biological applications make it an interesting subject of study.'

1,2,3,4-tetrahydroquinoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,2,3,4-tetrahydroquinoline : A member of the class of quinolines that is the 1,2,3,4-tetrahydro derivative of quinoline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69460
CHEMBL ID303611
CHEBI ID213323
SCHEMBL ID18172
MeSH IDM0538392

Synonyms (54)

Synonym
AC-2531
635-46-1
kusol
nsc-15311
1,3,4-tetrahydroquinoline
nsc15311
quinoline, 1,2,3,4-tetrahydro-
inchi=1/c9h11n/c1-2-6-9-8(4-1)5-3-7-10-9/h1-2,4,6,10h,3,5,7h
1,2,3,4-tetrahydroquinoline
1,2,3,4-tetrahydroquinoline, >=98%
1,2,3,4-tetrahydroquinoline, 98%
STK182862
tetrahydroquinoline
CHEMBL303611
1,2,3,4-tetrahydro-quinoline
T0113
chebi:213323 ,
1,2,3,4-tetrahydrochinoline
AKOS000119058
A843757
A8748
NCGC00188132-01
1,2,3,4,-tetrahydroquinoline
ccr50n1z9g ,
nsc 15311
ai3-10034
einecs 211-237-6
unii-ccr50n1z9g
FT-0606201
1,2,3,4-hydroquinoline
SCHEMBL18172
DTXSID8060903
1,2,3,4-tetra hydroquinoline
1,2,3,4tetrahydroquinoline
1,2,3,4- tetrahydroquinoline
1,2,3,4 tetrahydroquinoline
1,2,3,4-tetrahydoquinoline
1,2,3, 4-tetrahydroquinoline
1,2,3,4-tetrahydroquinolin
3,4-dihydro-2h-quinoline
1, 2,3,4-tetrahydroquinoline
TS-01727
Q-102341
mfcd00006693
F2190-0415
1,2,3,4-tetrahydroquinoline, purum, >=96.0% (gc)
1,2,3,4-tetrahydro quinoline
CS-D1404
SY001847
Q21099119
EN300-19046
AMY856
1,2,3,4-tetrahydroquinoline; 3,4-dihydro-2h-quinoline; kusol; nsc 15311; thq
Z104472414

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" During these studies the compound DM12 was identified as new, perspective and safe agent for adjuvant therapy."( Cytotoxic effects of new trans-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer.
Arenas, DR; Arvelo, F; Kouznetsov, VV; Muñoz, A; Sojo, F, 2011
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"The elimination kinetics of the pharmacologically active compound 1-ethyl-6-fluoro-1,2,3,4-tetrahydroquinoline (MC4) were characterized along with pharmacodynamic (PD) measurements."( Ocular pharmacokinetics of a novel tetrahydroquinoline analog in rabbit: compartmental analysis and PK-PD evaluation.
Pamulapati, CR; Schoenwald, RD, 2012
)
0.6

Bioavailability

ExcerptReferenceRelevance
" Optimization of these compounds for potency and pharmacokinetic properties led to the discovery of potent and orally bioavailable CRTH2 antagonists."( Tetrahydroquinoline derivatives as CRTH2 antagonists.
Anders, P; Liu, J; Marshall, D; Medina, J; Miao, S; Sun, Y; Tang, HL; Tocker, J; Tonn, G; Wang, Y, 2009
)
0.35
" These promising results, supported by the in silico prediction of high bioavailability and less potential risk than benznidazole, reveal several tetrahydroquinolines as prototypes of potential antichagasic drugs."( Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Kouznetsov, VV; Merchán Arenas, DR; Romero Bohórquez, AR, 2013
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Smad3Homo sapiens (human)Potency6.30960.00527.809829.0929AID588855
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
DNA polymerase kappa isoform 1Homo sapiens (human)Potency56.23410.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (198)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (3.54)18.7374
1990's1 (0.51)18.2507
2000's2 (1.01)29.6817
2010's136 (68.69)24.3611
2020's52 (26.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.34 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index6.21 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (4.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other190 (95.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]